Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.58 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.34 |
| ▸ | CDC25B | P30305 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SQLE | Q14534 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6907169 | 1.00 | PTPN1 (0.58) | PTPN1KDM1APTGS1PDE4ASNCA | |
| SCHEMBL6903691 | 0.92 | KDM1A (0.63) | PTPN1KDM1AMEN1CYP3A4ALOX15 | |
| SCHEMBL6903689 | 0.92 | KDM1A (0.63) | PTPN1KDM1AMEN1CYP3A4ALOX15 | |
| SCHEMBL13278036 | 0.92 | PTPN1 (0.71) | PTPN1KDM1APTGS1PDE4ASNCA | |
| SCHEMBL13277679 | 0.92 | PTPN1 (0.71) | PTPN1KDM1APTGS1PDE4ASNCA | |
| SCHEMBL13278035 | 0.92 | PTPN1 (0.71) | PTPN1KDM1APTGS1PDE4ASNCA | |
| SCHEMBL13277680 | 0.92 | PTPN1 (0.71) | PTPN1KDM1APTGS1PDE4ASNCA | |
| SCHEMBL14759468 | 0.86 | PTPN1 (0.42) | PTPN1KDM1AKMT2A | |
| SCHEMBL14759466 | 0.86 | PTPN1 (0.42) | PTPN1KDM1AKMT2A | |
| SCHEMBL163911 | 0.80 | PTPN1 (0.85) | PTPN1KDM1APTGS1PDE4ASNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4125735-A | Synthesis of esters of acetylenic alcohols | SCM CORPORATION (US) | 1978-11-14 | — | — | US | claimed |
| US-4115466-A | ACETYLENIC HYDROCARBONS FROM ACETYLENIC CARBINOLS, ISOMERIZATION | SCM CORPORATION (US) | 1978-09-19 | — | — | US | claimed |
| US-20230125249-A1 | USE OF VOLATILE COMPOUNDS TO MODULATE THE PERCEPTION OF MUSK | FIRMENICH SA (CH) | 2023-04-27 | — | — | US | disclosed |
| US-11530366-B2 | Use of volatile compounds to modulate the perception of musk | FIRMENICH SA (CH) | 2022-12-20 | — | — | US | disclosed |
| US-20200385648-A1 | USE OF VOLATILE COMPOUNDS TO MODULATE THE PERCEPTION OF MUSK | FIRMENICH, SA (CH) | 2020-12-10 | — | — | US | disclosed |
| EP-3703823-A1 | USE OF VOLATILE COMPOUNDS TO MODULATE THE PERCEPTION OF MUSK | Firmenich SA (CH) | 2020-09-09 | — | — | EP | disclosed |
| US-6703527-B2 | REACTING ALLYL ALCOHOL COMPOUND SUCH AS 2E,6E-3,7,11-TRIMETHYL-2,6,10-DODECATRIEN-1-OL WITH HYDRIDE ACCEPTOR SUCH AS 2-NITROBENZALDEHYDE IN THE PRESENCE OF AN ALUMINIUM ALKOXIDE AS AN OPPENAUER OXIDATION CATALYST | NIKKEN CHEMICALS CO., LTD. (JP) | 2004-03-09 | — | — | US | disclosed |
| US-20020198411-A1 | Method for oxidation of allyl alcohol | NIKKEN CHEMICALS CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| US-4125735-A | Synthesis of esters of acetylenic alcohols | SCM CORPORATION (US) | 1978-11-14 | — | — | US | disclosed |
| US-4055575-A | HYDROGENATION, SAPONIFICATION | SCM CORPORATION (US) | 1977-10-25 | — | — | US | disclosed |
| US-4039591-A | 1-ACETOXY-4-CHLORO-3-METHYLBUT-2-ENE | SCM CORPORATION (US) | 1977-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198411-A1 | Method for oxidation of allyl alcohol | ADH1A, ADH1C, ADH5 | PTPN1 4791/4885KDM1A 1170/4885PTGS1 1318/4885 |
| US-11530366-B2 | Use of volatile compounds to modulate the perception of musk | TRPA1, CMPK1, PLK3 | PTPN1 3463/4885KDM1A 3852/4885PTGS1 2102/4885 |
| US-20200385648-A1 | USE OF VOLATILE COMPOUNDS TO MODULATE THE PERCEPTION OF MUSK | TRPA1, CMPK1, PLK3 | PTPN1 3463/4885KDM1A 3852/4885PTGS1 2102/4885 |
| US-20230125249-A1 | USE OF VOLATILE COMPOUNDS TO MODULATE THE PERCEPTION OF MUSK | TRPA1, TRPM5, TRPM8 | PTPN1 3308/4885KDM1A 3722/4885PTGS1 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.